Salute e Benessere

PCR Technologies Market Share Worth $24.52 Billion, Globally, by 2030 -…

Download Sample Report :https://www.theinsightpartners.com/sample/TIPRE00003069/ Competitive Strategy and Development Global Headlines on PCR Technologies Identify the Key Trends Affecting This Market - Download Sample PDF: https://www.theinsightpartners.com/sample/TIPRE00003069/ Overview of Report Findings Market Segmentation Purchase Premium Copy of Global PCR Technologies Market Growth Report (2021-2031) at:https://www.theinsightpartners...
PR Newswire
17/10/2024

Body Contouring Treatments Market to Hit USD 2.58 Billion by 2029 with 10.0%…

Browse in-depth TOC on "Body Contouring Treatments Market"237 - Tables58 - Figures261 - Pages Browse in-depth TOC on "Body Contouring Treatments Market" 237 - Tables 58 - Figures 261 - Pages The body contouring treatments market is segmented based on technology into invasive and non-invasive technologies—the non-invasive segment is expected to hold major share of the market in 2023. The reduced risk of complications and rising awareness of the advantages of non-invasive...
PR Newswire
17/10/2024

Bioconjugation Market to Hit USD 10.86 Billion by 2029 with 15.6% CAGR |…

Browse in-depth TOC on "Bioconjugation Market" Browse in-depth TOC on "Bioconjugation Market" 1034 - Tables65 - Figures676 - Pages The market for bioconjugation has experienced significant growth also due to increasing investments in biopharmaceutical R&D, and growing demand for outsourcing services. The growing demand for biologics, such as monoclonal antibodies, antibody-drug conjugates (ADCs), and other protein-based drugs, is a major factor contributing to the...
PR Newswire
17/10/2024

Cancer: Crosetto's Breakthrough Inventions with Potential to Save Millions of…

They approved his six articles for presentation, their titles available at the conference program (https://www.eventclass.org/contxt_ieee2024/scientific/online-program/session?s=N-29), each supported by two pages accepted by reviewers, allocating Crosetto nearly two hours on October 31, 2024, 16:20 EST to present his 3D-Flow and 3D-CBS breakthrough inventions on particle detection and cancer detection at the world's most important conference in particle physics and medical imaging, in Tampa…
PR Newswire
17/10/2024

RenovaroCube Presents Novel Insights on Non-Invasive Cancer Diagnostics Using…

(NASDAQ: RENB)– RenovaroCube, a leader in AI-driven cancer diagnostics by integrating multi-omics with liquid biopsies, is excited to announce the presentation of its latest research at the Molecular Analysis for Precision Oncology Congress – on October 16, 2024.This study investigates the use of Oxford Nanopore sequencing on circulating cell-free DNA (cfDNA) derived from blood plasma to detect key copy number alterations (CNAs) in lung cancer patients. CNAs are a key hallmark of cancer...
Nasdaq GlobeNewswire
17/10/2024

Essity has received a demand for early repayment of bonds

NB: This information is such that Essity Aktiebolag (publ) is obligated to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 13:15 CET on October 17, 2024. NB:This information is such that Essity Aktiebolag (publ) is obligated to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out...
PR Newswire
17/10/2024

Endo Announces Seven New Presentations at the Sexual Medicine Society of North…

The seven Endo-sponsored and Endo-supported presentations are below: The seven Endo-sponsored and Endo-supported presentations are below: Sponsored by Endo: Investigator-Initiated Research: About Peyronie's DiseasePeyronie's disease (PD) is a condition in which a buildup of fibrous scar tissue causes a curvature deformity of the penis. This curvature can be painful during arousal and intimacy. 1It is estimated that PD can affect as many as 1 in 10 men in the U.S., 2but...
PR Newswire
17/10/2024

Fortrea Releases Inaugural Corporate Social Responsibility Report

Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced the release of the company's inaugural Corporate Social Responsibility report, “ Fortrea for Better.” Available for download onFortrea.com, the report describes Fortrea's environmental, social and governance (ESG) activities, reported across four distinct sections: Fortrea forLife : Responsible Environmental PracticesFortrea forAll : Responsible People PracticesFortrea forGood :...
Nasdaq GlobeNewswire
17/10/2024

Amplo Biotechnology Announces Three Presentations at the European Society of…

Details for the poster presentations: Details for the poster presentations: Abstract Title: Development of a platform gene therapy approach for Congenital Myasthenic SyndromesPresenting Author: Patricio V. Sepulveda S., PhD MBADate: Tuesday, October 22, 2024 Abstract Title:Pre-clinical development of gene augmentation therapy to restore Acetylcholinesterase activity in Collagen Q Congenital Myasthenic Syndrome using a platform approach to AAV gene therapy development...
PR Newswire
17/10/2024

KFSHRC Showcases Its Innovations and Health Solutions at the Global Health…

RIYADH, Saudi Arabia, Oct.17, 2024(GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) will participate as a Platinum Sponsor in the Global Health Exhibition 2024, held in Riyadh from October 21 to 23. Through its pavilion, KFSHRC will present its latest health innovations and solutions, showcasing their impact on improving healthcare outcomes, patient experience, and operational efficiency. These include robotic heart surgery, organ transplantation, CAR-T...
Nasdaq GlobeNewswire
17/10/2024

MolecuLight's Fluorescence Imaging: A Game-Changer for Bedside Biofilm Detection

"Fluorescence imaging demonstrated superior sensitivity (84%) compared to traditional methods of bedside biofilm detection," says Anil Amlani, CEO of MolecuLight Inc. "This underscores the transformative impact of our technology in managing a crucial issue affecting the outcomes of chronic wounds by providing clinicians with real-time, objective data that can significantly enhance patient outcomes." "Fluorescence imaging demonstrated superior sensitivity (84%) compared…
PR Newswire
17/10/2024

AscellaHealth Announces its Strategic Acquisition of CHAPPER healthcare: Expands…

AscellaHealth , a global partner delivering customizable solutions to support the specialty pharmaceutical industry, announces the acquisition of CHAPPER healthcare , a global specialty pharmaceutical wholesaler, distributor and services provider established in 1975. The acquisition of this recognized leader in the import and export of specialty pharmaceuticals deepens AscellaHealth's capabilities to serve international manufacturers and patients in more than 70 countries across the EU,...
Nasdaq GlobeNewswire
17/10/2024

Hisense Announces Dual Carbon Pledge at ESG Global Leaders Conference

"Hisense has embraced a 'long-termism' principle of implementing ESG practices as part of our 'Comprehensive Layout' and 'Global Action' strategy, which are integral to the company's commitment to ESG development," explained Mr. Jia. "The company has established a global network of '5+1' regional centers for research, production and sales. This adheres to a 'Local for Local' principle to contribute to and serve local communities, whilst reducing logistics costs and energy…
PR Newswire
17/10/2024

Cambrex Opens New Stability Storage Facility in Durham, North Carolina

Tom Loewald, Cambrex CEO, stated, "After acquiring Q1 Scientific in 2022, we have strategically expanded our footprint to best serve our clients worldwide. This first North American facility opening marks an important milestone in the growth of Q1 Scientific." Tom Loewald, Cambrex CEO, stated, "After acquiring Q1 Scientific in 2022, we have strategically expanded our footprint to best serve our clients worldwide. This first North American facility opening marks an important…
PR Newswire
17/10/2024

Finnish municipality has chosen Aino

Yet another Finnish municipality, Siilinjärvi, has chosen Aino's SaaS platform to be more socially sustainable and to achieve the operational goals with the existing staff. The agreement includes a total of 850 employees and the SaaS platform is in production use since the third quarter of 2024. “As a public organization we are working hard every day to find and to keep employees with the right competence. With Aino we will gain a more systematic and responsive leadership, boost employee...
Nasdaq GlobeNewswire
17/10/2024

CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI®…

"Swissmedic approval further demonstrates our promise to deliver transformational medicines for patients with serious diseases in our areas of focus," said Emmanuelle Lecomte Brisset, Senior Vice President and Head of Global Regulatory Affairs at CSL. "There is a high unmet medical need for a targeted therapy to treat IgAN and we look forward to providing access to this innovative treatment option for the Swiss IgAN community as fast as possible. Thank you to all of the patients…
PR Newswire
17/10/2024

Bio X Cell Announces Board of Director Appointments

"We are thrilled to welcome Alan Hirzel to the board alongside Kevin Ballinger, who joined earlier this year," said Chris Conway, CEO of Bio X Cell. "Alan and Kevin bring a wealth of experience and industry knowledge to the table, which will serve us well as we execute on BXC's extraordinary strategic growth opportunities following the Company's recent acquisition by Windjammer Capital Investors." "We are thrilled to welcome Alan Hirzel to the board alongsideKevin…
PR Newswire
17/10/2024

Press Release: Sanofi and Orano join forces to develop next-generation…

Sanofi and Orano join forces to develop next-generation radioligand medicinesParis, October 17, 2024.Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targeted alphatherapies in oncology, have entered into an agreement to combine their expertise in the fight against rare cancers and further accelerate the development of next-generation radioligand medicines.Building on the expertise and radioligand pipeline of Orano Med, Sanofi and Orano will...
Nasdaq GlobeNewswire
17/10/2024

Press Release: Sanofi and Orano join forces to develop next-generation…

Sanofi and Orano join forces to develop next-generation radioligand medicinesParis, October 17, 2024.Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targeted alphatherapies in oncology, have entered into an agreement to combine their expertise in the fight against rare cancers and further accelerate the development of next-generation radioligand medicines.Building on the expertise and radioligand pipeline of Orano Med, Sanofi and Orano will...
Nasdaq GlobeNewswire
17/10/2024

Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results

Press ReleaseNicox Provides Third Quarter 2024 update and First Half 2024 Financial Results Topline results from the NCX 470 (bimatoprost grenod) Phase 3 Denali clinical trial expected in Q3 2025Cash of €19.7 million on September 30, 2024, including the estimated net proceeds of the VYZULTA royalty sale and equity investment announced on October 14, 2024The Company estimates that it is financed into Q3 2025October 17, 2024 – release at 7:30 am CETSophia...
Nasdaq GlobeNewswire
17/10/2024

Hansa Biopharma Reports Third Quarter and Interim January - September 2024…

Søren Tulstrup, President and CEO, Hansa Biopharma said, "The third quarter of 2024 marks the highest ever IDEFIRIX® sales performance to date, resulting in four consecutive quarters of strong sales performance. The launch of IDEFIRIX in Europe continues to advance with adoption in international organ allocation systems and an increase in new and repeat utilization in leading transplant clinics. Equally, we see strong momentum in our clinical development programs in autoimmune, gene therapy…
PR Newswire
17/10/2024

Eisai will request reconsideration of initial decision for lecanemab in…

Lecanemab is already approved in the United States, Japan, China, South Korea, Hong Kong, Israel UAE and Great Britain, and is being marketed in the United States, Japan and China. Lecanemab is already approved inthe United States,Japan,China,South Korea,Hong Kong, Israel UAE andGreat Britain, and is being marketed inthe United States,JapanandChina. Lecanemab is the result of a long-standing collaboration between BioArctic and Eisai, and the antibody was...
PR Newswire
17/10/2024

PARP Inhibitors Market to Register Immense Growth by 2034 Owing to Wider…

Key Takeaways from the PARP Inhibitors Market Report Key Takeaways from the PARP Inhibitors Market Report Discover which therapies are expected to grab the PARP inhibitors market share @ PARP Inhibitors Market Report PARP Inhibitors Market Dynamics The PARP inhibitors market has seen significant growth and transformation in recent years, driven primarily byadvancements in oncologyand theincreasing recognition of these drugs' therapeutic potential. One of the key dynamics...
PR Newswire
16/10/2024

Innocan Pharma to Participate at the ThinkEquity 2024 Investor Conference in New…

Iris Bincovich, CEO of Innocan Pharma, will be presenting at the investor conference on Wednesday, October 30th at 2:00pm ET (also viewable online at the conference portal). The Company's executive team will be available for one-on-one meetings at the event. Iris Bincovich, CEO of Innocan Pharma, will be presenting at the investor conference onWednesday, October 30th at2:00pm ET (also viewable online at the conference portal). The Company's executive team will be available for one-on-one...
PR Newswire
16/10/2024
Altri  Comunicati